SCHEMBL1707833

SCHEMBL1707833

Cc1nc(N2CCOCC2)nc(C)c1Br

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.56
KDM4E B2RXH2 4/20 0.56
HPGD P15428 2/20 0.56
KMT2A Q03164 3/20 0.51
SMN1; SMN2 Q16637 4/20 0.47
MAPK1 P28482 4/20 0.47
PIK3CA P42336 2/20 0.45
PIK3R1 P27986 1/20 0.45
MTOR P42345 1/20 0.45
NPSR1 Q6W5P4 2/20 0.45
HRH4 Q9H3N8 1/20 0.45
LMNA P02545 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
HTT P42858 1/20 0.44
PIK3CD O00329 1/20 0.44
PIK3CB P42338 1/20 0.44
PIK3CG P48736 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26337500 0.83 ALDH1A1 (0.59) ALDH1A1KDM4EHPGDKMT2ASMN1; SMN2
SCHEMBL11828286 0.81 HTR2C (0.48) ALDH1A1KDM4EHPGDKMT2ASMN1; SMN2
SCHEMBL1707790 0.81 ALDH1A1 (0.49) ALDH1A1KDM4EHPGDKMT2ASMN1; SMN2
SCHEMBL15207184 0.80 ALDH1A1 (0.56) ALDH1A1KDM4EHPGDKMT2ASMN1; SMN2
SCHEMBL3094653 0.80 ALDH1A1 (0.56) ALDH1A1KDM4EHPGDKMT2ASMN1; SMN2
SCHEMBL8973821 0.78 HTT (0.63) ALDH1A1KDM4EHPGDKMT2ASMN1; SMN2
SCHEMBL20604725 0.78 KMT2A (0.56) KMT2ANPSR1HRH4HSD17B10TP53
SCHEMBL19105591 0.77 KMT2A (0.53) ALDH1A1KDM4EHPGDKMT2ASMN1; SMN2
SCHEMBL12110268 0.77 KMT2A (0.56) ALDH1A1KDM4EHPGDKMT2ASMN1; SMN2
SCHEMBL9619196 0.77 KDM4E (0.58) ALDH1A1KDM4EHPGDKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303573-A1 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives Grünenthal GmbH (DE) 2023-09-28 US disclosed
EP-3722284-A1 3-((HETERO-)ARYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES Grünenthal GmbH (DE) 2020-10-14 EP disclosed
EP-3402781-B1 3-((HETERO-)ARYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES GRUENENTHAL GMBH (DE) 2020-03-04 EP disclosed
US-20120172351-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-05 US disclosed
EP-2440541-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-04-18 EP disclosed
WO-2010143733-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303573-A1 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives OPRK1, OPRD1, OPRL1 ALDH1A1 337/4885KDM4E 2919/4885HPGD 726/4885
US-20120172351-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF GPR119, INSR, GLP1R ALDH1A1 3930/4885KDM4E 3896/4885HPGD 3215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.